

ADVANCED HEPATOMA

Sequence of therapies

CLINICAL CASE PRESENTATION

Daire Hanna

Royal Free London NHS Foundation Trust, London,
United Kingdom

DISCLOSURE


No conflict of interest

Case Report Mr. H.T.

ED 02/2017: well-differentiated HCC
ø 6 cm


Co-morbidities:

- 69 years
- ECOG 1, 176cm, 89 kg
- AFP not elevated
- NAFLD
- Child Pugh A, ALBI 2 (Bili)
- Diabetes mellitus
- Hypertension



Case Report Mr. H.T.: Treatment


04/2017: 1. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)



Case Report Mr. H.T.: Treatment

04/2017: 1. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)

04/2017: 2. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)



Case Report Mr. H.T.: Treatment

04/2017: 1. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)

04/2017: 2. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)

Best Response:
Stable disease



Question 1. How would you treat now?

.... still CP A, ALBI 2, ECOG 0-1

1. Continue with TACE (this is still TACable...)
2. Switch to SIRT (we should try something new....)
3. Switch to systemic therapy (enough is enough....)

Please choose one option

Case Report Mr. H.T.: Treatment

04/2017: 1. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)

04/2017: 2. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)

06/2017: Sorafenib

12/2017: Sorafenib SD

04/2018: Sorafenib PD



Question 2. How would you treat now?

.... still CP A, ALBI 2, ECOG 0-1, no AFP

1. Sorafenib
2. Regorafenib
3. Cabozantinib
4. Ramucirumab
5. Pembrolizumab
6. Nivolumab

Please choose one option

Case Report Mr. H.T.: Treatment

04/2017: 1. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)

04/2017: 2. TACE
(75mg Doxorubicin/
30 – 60um Hepaspheres)

06/2017: Sorafenib

12/2017: Sorafenib SD

04/2018: Sorafenib PD

05/2018: Pembrolizumab

06/2019: CR ongoing



CR, complete response/remission; PD,
progressive disease; SD, stable disease

Question 3. How would you continue now?

still CP A, ALBI 2, ECOG 0-1

1. Continue with Pembrolizumab for 1 year
2. Continue with Pembrolizumab for 2 years
3. Treat until progression

Please choose one option

Thank you